Scottish Medicines Consortium accepts five new drugs

The Scottish Medicines Consortium (SMC) has accepted five new drugs for routine use by NHS Scotland, including treatments for breast cancer, myeloma and attention deficit hyperactivity disorder (ADHD).  One of the medicines, fulvestrant (Faslodex), which is used for advanced breast cancer, was accepted following consideration under the SMC’s Patient and Clinician Engagement Process (PACE), which aims to improve patient access to new medicines for the treatment of end of life and very rare conditions. During the PACE meeting, it was highlighted that fulvestrant can delay the time to chemotherapy for some patients. It provides an alternative treatment option for patients